Study of HH2853 for relapsed or refractory peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these types of T-cell lymphoma: PTCL-NOS, AITL, ALK+ ALCL, ALK- ALCL, NKTCL, enteropathy-associated T-cell lymphoma, or others as listed.
- Your lymphoma has come back or not responded after at least one prior treatment (and usually no more than 4 to 5 previous treatments).
- You can perform daily activities without help (ECOG score 0 or 1).
- Your organs (bone marrow, liver, kidneys) are working well enough, as shown by blood tests.
- You must provide a tissue sample from a biopsy for central lab testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This study tests an experimental pill (SHR2554) as maintenance therapy after your first treatment for peripheral T-cell lymphoma has worked. The goal is to see if it helps keep the cancer from coming back.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
Hear when a new Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.